-
Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: Mandatory notification for close associate
-
Ultimovacs ASA: Third quarter 2021 result presentation
-
Ultimovacs’ SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma
-
Ultimovacs ASA: Invitation to third quarter 2021 results presentation
-
Ultimovacs ASA – New share capital registered
-
Ultimovacs ASA – Transactions by primary insiders and closely associated parties
-
Ultimovacs ASA – Private placement of new shares successfully placed
